Featured Publications
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Jaycox J, Lucas C, Yildirim I, Dai Y, Wang E, Monteiro V, Lord S, Carlin J, Kita M, Buckner J, Ma S, Campbell M, Ko A, Omer S, Lucas C, Speake C, Iwasaki A, Ring A. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nature Communications 2023, 14: 1299. PMID: 36894554, PMCID: PMC9996559, DOI: 10.1038/s41467-023-36686-8.Peer-Reviewed Original ResearchConceptsVaccine-associated myocarditisAutoimmune patientsAutoantibody reactivitySARS-CoV-2 mRNA vaccinationVaccine-related adverse effectsSARS-CoV-2 immunitySARS-CoV-2 infectionAcute COVID-19Development of autoantibodiesCOVID-19 patientsAnti-viral immunityVirus-specific antibodiesCOVID-19 vaccineCOVID-19Humoral autoimmunityMRNA vaccinationAutoantibody responsePost vaccinationAutoantibody developmentAutoimmune diseasesHumoral responseHealthy individualsPatientsAntigen profilingAdverse effects
2021
Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Arrieta AC, Neely M, Day JC, Rheingold SR, Sue PK, Muller WJ, Danziger-Isakov LA, Chu J, Yildirim I, McComsey GA, Frangoul HA, Chen TK, Statler VA, Steinbach WJ, Yin DE, Hamed K, Jones ME, Lademacher C, Desai A, Micklus K, Phillips DL, Kovanda LL, Walsh TJ. Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00290-21. PMID: 34031051, PMCID: PMC8284446, DOI: 10.1128/aac.00290-21.Peer-Reviewed Original ResearchConceptsPhase 1 studyPediatric patientsIsavuconazonium sulfatePlasma drug exposureDrug exposureOral administrationImmunocompromised Pediatric PatientsNew triazole agentProdrug isavuconazonium sulfateTolerability of isavuconazoleBody mass indexPopulation PK modelInvasive fungal infectionsProbability of targetTarget rangeConcentration-time curveFirst-order inputMass indexPopulation pharmacokineticsStepwise covariate modelingTriazole agentsClinical dosePK parametersLinear eliminationPatientsRisk of Disseminated Gonococcal Infections With Terminal Complement Blockade
Graciaa SH, Graciaa DS, Yildirim I, Chonat S. Risk of Disseminated Gonococcal Infections With Terminal Complement Blockade. Journal Of Pediatric Hematology/Oncology 2021, 44: e493-e495. PMID: 33560079, PMCID: PMC8556643, DOI: 10.1097/mph.0000000000002075.Peer-Reviewed Original ResearchConceptsTerminal complement blockadeComplement blockadeGonococcal infectionClonal hematopoietic stem cell disordersDisseminated gonococcal infectionHematopoietic stem cell disordersQuality of lifeStem cell disordersParoxysmal nocturnal hemoglobinuriaComplement protein C5Complement-mediated hemolysisProphylactic antibioticsIntravascular hemolysisAppropriate immunizationsAzithromycin resistanceCell disordersNocturnal hemoglobinuriaNeisseria gonorrhoeaeProtein C5Infection riskPatientsMonoclonal antibodiesNeisseria meningitidisBlockadeInfection
2020
Pulmonary Infections in the Immunocompromised Host
Yildirim I, Gibson J, Danziger-Isakov L. Pulmonary Infections in the Immunocompromised Host. Respiratory Medicine 2020, 235-252. DOI: 10.1007/978-3-030-54924-4_20.Peer-Reviewed Original ResearchPulmonary infectionHematopoietic stem cell transplantationCurrent immune statusSolid organ transplantationStem cell transplantationPrimary immunodeficiency patientsImmunocompromised childrenCommon complicationImmune compromiseImmunocompromised hostPulmonary diseaseBronchoalveolar lavageImaging findingsClinical symptomsCell transplantationImmune statusImmunodeficiency patientsInvasive studiesOrgan transplantationHigh riskCommon pathogensPatientsInfectionExposure historyTransplantationInitial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole
Bernardo V, Miles A, Fernandez AJ, Liverman R, Tippett A, Yildirim I. Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole. Pediatric Transplantation 2020, 24: e13777. PMID: 32639095, DOI: 10.1111/petr.13777.Peer-Reviewed Original ResearchConceptsYears of ageMedian daily doseTrough concentrationsDaily dosePlasma concentrationsYoung adultsPlasma trough concentrationsSerum posaconazole concentrationsInvasive fungal diseaseTherapeutic plasma concentrationsDelayed-release tabletsIntravenous posaconazolePosaconazole dosingImmunocompromised childrenPatients 13Optimal dosingBroad-spectrum antifungalsAdolescent patientsPosaconazole concentrationsHigher dosingPatientsBody weightGrade 1ProphylaxisDosing
2019
Sirolimus‐associated pericardial effusion with cardiac tamponade and interstitial pneumonitis in a hematopoietic stem cell transplant recipient
Joo SJ, Yildirim I, Stenger EO, Anderson EJ. Sirolimus‐associated pericardial effusion with cardiac tamponade and interstitial pneumonitis in a hematopoietic stem cell transplant recipient. Pediatric Transplantation 2019, 23: e13425. PMID: 31012209, DOI: 10.1111/petr.13425.Peer-Reviewed Original ResearchConceptsHSCT patientsCardiac tamponadeInterstitial pneumonitisPericardial effusionAllogeneic hematopoietic stem cell transplant patientsHematopoietic stem cell transplant recipientsHematopoietic stem cell transplant patientsStem cell transplant patientsStem cell transplant recipientsAllogeneic HSCT patientsCell transplant recipientsLife-threatening complicationsCell transplant patientsTreatment of graftInvasive fungal infectionsGVHD prophylaxisHost diseaseTransplant patientsTransplant recipientsSirolimus useRapamycin inhibitorsPotent immunosuppressantPatientsFungal infectionsMammalian target
2015
Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine
Yildirim I, Shea KM, Pelton SI. Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine. Infectious Disease Clinics Of North America 2015, 29: 679-697. PMID: 26610421, PMCID: PMC4662776, DOI: 10.1016/j.idc.2015.07.009.Peer-Reviewed Original ResearchConceptsPneumococcal conjugate vaccinePneumococcal diseaseConjugate vaccineOtitis mediaUniversal immunizationAcute otitis mediaInvasive pneumococcal diseaseCase fatality rateVulnerable pediatric patientsSpectrum of serotypesCause pneumoniaPediatric patientsComorbid conditionsHealthy childrenFatality rateDiseaseHost susceptibilityImmunizationVaccineHigh rateChildrenEmpyemaMastoiditisPneumoniaPatients
2010
A Case Report of Thrombocytopenia‐associated Multiple Organ Failure Secondary to Salmonella enterica Serotype Typhi Infection in a Pediatric Patient: Successful Treatment With Plasma Exchange
Yildirim I, Ceyhan M, Bayrakci B, Uysal M, Kuskonmaz B, Ozaltin F. A Case Report of Thrombocytopenia‐associated Multiple Organ Failure Secondary to Salmonella enterica Serotype Typhi Infection in a Pediatric Patient: Successful Treatment With Plasma Exchange. Therapeutic Apheresis And Dialysis 2010, 14: 226-229. PMID: 20438547, DOI: 10.1111/j.1744-9987.2009.00714.x.Peer-Reviewed Original ResearchConceptsSalmonella enterica serotype Typhi infectionMultiple organ failureS. typhi infectionTyphi infectionOrgan failurePlasma exchangeAggressive antimicrobial therapyPlasma exchange therapyLife-saving interventionsConventional supportive measuresSevere sepsisExchange therapyPediatric patientsCase reportAntimicrobial therapySuccessful treatmentSupportive measuresMortality rateAntimicrobial treatmentPatientsThrombocytopeniaInfectionTherapyHigher proportionTreatmentRisks and outcome of fungal infection in neutropenic children with hematologic diseases.
Aytaç S, Yildirim I, Ceyhan M, Cetin M, Tuncer M, Kara A, Cengiz AB, Seçmeer G, Yetgin S. Risks and outcome of fungal infection in neutropenic children with hematologic diseases. The Turkish Journal Of Pediatrics 2010, 52: 121-5. PMID: 20560245.Peer-Reviewed Original ResearchConceptsFebrile neutropenic episodesAcute myeloid leukemiaNeutropenic episodesAcute lymphoblastic leukemiaAplastic anemiaAntifungal treatmentFungal infectionsMortality rateAmphotericin BNeutropenic childrenRetrospective studyLymphoblastic leukemiaMyeloid leukemiaHematologic diseasesTreatment groupsPatientsWhole groupInfectionEpisodesLeukemiaMortalityAnemiaGroupDiseaseFluconazole
2008
A Chryseobacterium meningosepticum outbreak observed in 3 clusters involving both neonatal and non-neonatal pediatric patients
Ceyhan M, Yıldırım I, Tekelı A, Yurdakok M, Us E, Altun B, Kutluk T, Cengiz AB, Gurbuz V, Barın C, Bagdat A, Cetınkaya D, Gur D, Tuncel O. A Chryseobacterium meningosepticum outbreak observed in 3 clusters involving both neonatal and non-neonatal pediatric patients. American Journal Of Infection Control 2008, 36: 453-457. PMID: 18675153, DOI: 10.1016/j.ajic.2007.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsChryseobacteriumCluster AnalysisCross InfectionDisease OutbreaksDNA FingerprintingDNA, BacterialEnvironmental MicrobiologyFemaleFlavobacteriaceae InfectionsGenotypeHandHealth PersonnelHospital UnitsHumansInfantInfant, NewbornMaleMicrobial Sensitivity TestsRandom Amplified Polymorphic DNA TechniqueTurkeyConceptsNon-neonatal pediatric patientsHealth care workers' handsNeonatal intensive care unitTertiary health centerEnterobacterial repetitive intergenic consensus sequence polymerase chain reactionIntensive care unitInfection control measuresMeningosepticum infectionOlder patientsPediatric patientsPremature infantsCare unitPediatric wardPolymerase chain reactionHand culturesHealth centersIndex patientsNosocomial infectionsAmbu bagPatientsEtiologic agentAntimicrobial treatmentPowdered infant formulaOutbreak investigationInfant formulaCytomegalovirus hepatitis and ganciclovir treatment in immunocompetent children.
Tezer H, Seçmeer G, Kara A, Ceyhan M, Cengiz AB, Devrim I, Us D, Yüce A, Gürakan F, Yildirim I, Ozen H, Saltik-Temizel IN. Cytomegalovirus hepatitis and ganciclovir treatment in immunocompetent children. The Turkish Journal Of Pediatrics 2008, 50: 228-34. PMID: 18773667.Peer-Reviewed Original ResearchConceptsBiliary atresiaGanciclovir treatmentCauses of hepatitisCongenital CMV infectionExtrahepatic biliary atresiaSigns of infectionCMV hepatitisCholestatic hepatitisCMV infectionCytomegalovirus infectionImmunocompetent childrenStudy groupHepatitisPatientsGroup IIDemographic featuresGroup IInborn errorsInfectionAtresiaChildrenTreatmentGroupGenetic diseasesCMV